Cardiff Oncology is a clinical-stage biotechnology company built around a single, scientifically validated target: Polo-like kinase 1 (PLK1), an enzyme that plays a central role in cell division and is frequently dysregulated in aggressive cancers. Its lead asset, onvansertib, is an oral, highly specific PLK1 inhibitor being developed primarily for first-line RAS-mutated mCRC, where standard-of-care chemotherapy regimens have delivered limited progression-free survival (PFS) and where meaningful innovation has been scarce for more than two decades.
That clinical unmet need is the core of Cardiff's market positioning. No PLK1 inhibitor has yet reached approval, and onvansertib's mutation-agnostic mechanism could distinguish it from therapies that target only a narrow subset of RAS mutations. The company is also broadening its scientific footprint through investigator-initiated studies in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC), as well as preclinical work combining onvansertib with antibody-drug conjugates. Medium-term, the investment thesis rests on executing a registrational trial and, potentially, attracting a partner or acquirer to commercialize the asset. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Several forward-looking catalysts are likely to drive investor sentiment. First, the company has completed an End-of-Phase 2 meeting with the FDA and selected a 30-milligram onvansertib dose for a Phase 3 registrational trial; the full trial design and regulatory strategy are expected to be detailed in mid-2026. Second, updated CRDF-004 data presented at major medical conferences—including the American Society of Clinical Oncology (ASCO) annual meeting—could provide more mature durability and PFS signals that either reinforce or temper enthusiasm.
On the analyst front, the consensus profile is constructive but not uniform. Firms including Ladenburg Thalmann and H.C. Wainwright have maintained Buy ratings with price targets as high as $19 and $10, respectively, while Jefferies has taken a more cautious stance with a Hold rating and a $3.50 target. TD Cowen and William Blair have also maintained Buy ratings. This divergence means that any shift in the consensus price target or rating distribution—upward or downward—could move the stock meaningfully, given the wide gap between the lowest and highest published targets. From what I see, monitoring these shifts remains essential for CRDF investors.
Cardiff's trajectory is closely tied to the broader biotech financing cycle. Interest rates and risk appetite in capital markets influence both the cost of raising equity and the willingness of large pharmaceutical companies to strike licensing or acquisition deals. A more accommodative rate environment typically supports pre-revenue, clinical-stage names, while tighter conditions can pressure valuations and accelerate dilution as companies fund multi-year trials.
Within oncology, demand for innovative first-line colorectal cancer therapies remains structurally strong, driven by an aging population and high mortality in the metastatic setting. Regulatory tailwinds—such as the FDA's openness to accelerated approval pathways for drugs addressing serious unmet needs—could shorten onvansertib's path to market. At the same time, competitive intensity in RAS-targeted therapies is rising, which could compress the commercial opportunity even if clinical success is achieved. One thing that stands out is how these macro factors interact with the company's clinical progress.
Looking into 2026 and beyond, Cardiff's future outlook hinges on its ability to launch and successfully enroll a global Phase 3 trial while preserving a disciplined cost structure. Management has indicated sufficient capital to support operations into 2027, but advancing a registrational program will likely require additional funding—making the timing and terms of future capital raises a central watch item for investors.
Longer term, the key structural drivers include potential market expansion beyond mCRC into pancreatic, lung, and breast cancers; the durability of onvansertib's efficacy and safety profile in larger patient populations; and whether the company can secure a commercialization partner. Cost-structure evolution and margin sustainability matter less today than cash runway and trial execution, but they will become increasingly relevant as the program approaches potential regulatory filing, which some external research estimates place toward the end of the decade. Consensus analyst price targets, while wide-ranging, reflect a base expectation of substantial upside if the Phase 3 program validates the Phase 2 signals—while underscoring that the outcome remains speculative and dependent on successful execution. I’m watching this closely as the data matures.
In my research process, I frequently use the AI Trend Prediction Engine to evaluate near-term momentum for names like CRDF. This AI-powered tool provides forecasts on whether a stock may trend bullish, bearish, or sideways over the coming weeks or months, offering searchable predictions, historical context, and alerts that complement fundamental analysis. It serves as a practical data-driven lens for tracking potential breakouts or reversals alongside longer-term clinical developments.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The Aroon Indicator for CRDF entered a downward trend on November 20, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 252 similar instances where the Aroon Indicator formed such a pattern. In 215 of the 252 cases the stock moved lower. This puts the odds of a downward move at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRDF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CRDF's RSI Oscillator exited the oversold zone, 24 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 58 cases where CRDF's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on CRDF as a result. In 76 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for CRDF just turned positive on November 16, 2026. Looking at past instances where CRDF's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.
Following a +6.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRDF advanced for three days, in 208 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
CRDF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. CRDF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.332) is normal, around the industry mean (3.596). P/E Ratio (-1.326) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (178.571) is also within normal values, averaging (443.347).
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRDF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors
Industry Biotechnology